Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence.
暂无分享,去创建一个
Wei Shi | Rex Moats | Ryan Park | Anton Berns | Chun-Peng Liao | Chun-Peng Liao | P. Roy-Burman | A. Berns | J. Bading | R. Moats | P. Conti | A. Nikitin | C. Zhong | R. Park | W. Shi | Zong-xiang Zhou | Peter S Conti | Chen Zhong | Gohar Saribekyan | James Bading | Zongxiang Zhou | Alexander Yu Nikitin | Pradip Roy-Burman | G. Saribekyan | P. Roy‐Burman | P. Roy-burman
[1] A. DeMaria,et al. Diagnostic, Prognostic and Therapeutic Implications , 1974 .
[2] G Dhom,et al. Relation of endocrine‐paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate , 1991, The Prostate.
[3] P. A. Sant'agnese,et al. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. , 1992 .
[4] P. A. Sant'agnese,et al. Neuroendocrine differentiation in human prostatic carcinoma , 1992 .
[5] P. di Sant'Agnese,et al. Neuroendocrine differentiation in human prostatic carcinoma. , 1992, Human pathology.
[6] P. di Sant'Agnese,et al. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications , 1992, Cancer.
[7] P. di Sant'Agnese,et al. Neuroendocrine cells in the human prostate gland. , 1993, Journal of andrology.
[8] C. Logothetis,et al. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. , 1993, The Journal of urology.
[9] K Remberger,et al. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. , 1995, Human pathology.
[10] A. Partin,et al. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. , 1996, Human pathology.
[11] N. Rubio,et al. Metastatic burden in nude mice organs measured using prostate tumor PC‐3 cells expressing the luciferase gene as a quantifiable tumor cell marker , 2000, The Prostate.
[12] T. H. van der Kwast,et al. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. , 2000, Cancer research.
[13] R. Matusik,et al. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. , 2000, Endocrinology.
[14] T. Kwast,et al. Androgen Deprivation of the Prohormone Convertase-310 Human Prostate Cancer Model System Induces Neuroendocrine Differentiation , 2000 .
[15] R. Young,et al. Tumors of the Prostate Gland, Seminal Vesicles, Male Urethra, and Penis , 2000 .
[16] N. Greenberg,et al. Prostate specific expression of Cre recombinase in transgenic mice , 2000, Genesis.
[17] Jos Jonkers,et al. A highly efficient ligand‐regulated Cre recombinase mouse line shows that LoxP recombination is position dependent , 2001, EMBO reports.
[18] P. A. Sant'agnese,et al. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] M. Tachibana,et al. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence. , 2001, Oncology reports.
[20] M. Poutanen,et al. Improved technique for detection of enhanced green fluorescent protein in transgenic mice. , 2001, BioTechniques.
[21] P. Roy-Burman,et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation , 2001, Mechanisms of Development.
[22] B. Rice,et al. In vivo imaging of light-emitting probes. , 2001, Journal of biomedical optics.
[23] P. di Sant'Agnese,et al. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] Y Fujiwara,et al. Activation of EGFP expression by Cre-mediated excision in a new ROSA26 reporter mouse strain. , 2001, Blood.
[25] P. Roy-Burman,et al. Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium. , 2002, Cancer research.
[26] N. Rubio,et al. Combined Noninvasive Imaging and Luminometric Quantification of Luciferase-Labeled Human Prostate Tumors and Metastases , 2002, Laboratory Investigation.
[27] S. Gambhir,et al. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging , 2002, Nature Medicine.
[28] Peter A. Humphrey,et al. Conditional Loss of Nkx3.1 in Adult Mice Induces Prostatic Intraepithelial Neoplasia , 2002, Molecular and Cellular Biology.
[29] M. Groszer,et al. Cre/loxP‐mediated inactivation of the murine Pten tumor suppressor gene , 2002, Genesis.
[30] P. Nelson,et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.
[31] Anton Berns,et al. The generation of a conditional reporter that enables bioluminescence imaging of Cre/loxP-dependent tumorigenesis in mice. , 2003, Cancer research.
[32] S. Gambhir,et al. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.
[33] P. Pandolfi,et al. Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.
[34] P. Abrahamsson. Neuroendocrine differentiation in prostatic carcinoma , 1999, The Prostate.
[35] D. Jenkins,et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis , 2004, Clinical & Experimental Metastasis.
[36] C. Scatena,et al. Imaging of bioluminescent LNCaP‐luc‐M6 Tumors: A new animal model for the study of metastatic human prostate cancer , 2004, The Prostate.
[37] Xiaoming Xie,et al. The EZC-prostate model: noninvasive prostate imaging in living mice. , 2004, Molecular endocrinology.
[38] P. Abrahamsson,et al. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. , 2005, European urology.
[39] T. H. van der Kwast,et al. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. , 2005, Cancer research.
[40] S. Lyons. Advances in imaging mouse tumour models in vivo , 2005, The Journal of pathology.
[41] D. Tindall,et al. Letter to the Editor: Androgens and Prostate Cancer: Are the Descriptors Valid? , 2005, Cancer biology & therapy.
[42] W. D. Martin,et al. A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals. , 2005, Journal of molecular endocrinology.
[43] Jason A. Koutcher,et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.
[44] C. Sawyers,et al. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. , 2006, Cancer research.
[45] S. Lyons,et al. Noninvasive bioluminescence imaging of normal and spontaneously transformed prostate tissue in mice. , 2006, Cancer research.
[46] P. di Sant'Agnese,et al. Immunohistochemical characterization of neuroendocrine cells in prostate cancer , 2006, The Prostate.
[47] Hong Wu,et al. Increased expression of osteopontin contributes to the progression of prostate cancer. , 2006, Cancer research.
[48] Shunyou Wang,et al. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[49] Chun-Peng Liao,et al. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. , 2006, Cancer research.
[50] David C. Corney,et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.